# Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/neoadjuvant-pamiparib-plus-abiraterone-and-androgen-deprivation-therapy-for-high/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tangtao Gong,Shuo Liang,Zhigang Wu,Xuefeng Qiu,L. Xu,Shan Peng,H. Guo,S. Zhang,Junlong Zhuang |
| Citations | 0 |
| DOI | 10.1038/s41391-025-01068-2 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W7117322425 |
| PMID | 41454188 |
| Type | article |
| Year | 2025 |

## Paper authors

- [H. Guo](https://scholariq.org/researchers/h-guo/)

## Paper primary topic

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Paper topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.